AP01
Idiopathic Pulmonary Fibrosis · ANZCTR
Clinical trials
2
Mechanism
ANZCTR
Developer
Avalyn Pharma Inc.
Overview
AP01 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via anzctr. It appears in 2 tracked IPF clinical trials.
AP01 clinical trials
Explore related
Medical disclaimer. This page summarizes research about AP01 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.